magrolimab + pomalidomide + dexamethasone

Magrolimab + pomalidomide + dexamethasone is an investigational three-drug combination therapy for relapsed/refractory multiple myeloma, currently in phase II clinical studies. **Magrolimab** is a humanized monoclonal antibody that targets and blocks CD47, a "do not eat me" signal overexpressed on tumor cells, enhancing macrophage-mediated phagocytosis and elimination of myeloma cells[1][2][3][4]. **Pomalidomide** is an immunomodulatory small molecule that binds cereblon, part of the ubiquitin ligase complex, inhibiting proliferation and inducing apoptosis of tumor cells, and also boosts T cell and NK cell responses[1]. **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and antineoplastic effects. The combination aims to provide non-overlapping, synergistic anti-myeloma activity, with magrolimab enhancing innate immune cell-mediated tumor elimination and pomalidomide/dexamethasone contributing immunomodulatory and cytotoxic effects[1][3]. The regimen is under clinical development sponsored by Gilead Sciences for use in patients with multiple myeloma who have failed prior therapies[1][3][4][6].

Other names

magrolimab + pomalidomide + dexamethasone